Premium
Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis
Author(s) -
Turner Martin R.,
Benatar Michael
Publication year - 2015
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.24470
Subject(s) - amyotrophic lateral sclerosis , biomarker , medicine , clinical trial , replication (statistics) , neuroscience , physical medicine and rehabilitation , bioinformatics , pathology , biology , disease , genetics , virology
ABSTRACT Multiple candidate biomarkers for amyotrophic lateral sclerosis (ALS) have emerged across a range of platforms. Replication of results, however, has been absent in all but a few cases, and the range of control samples has been limited. If progress toward clinical translation is to continue, the specific biomarker needs of ALS, which differ from those of other neurodegenerative disorders, as well as the challenges inherent to longitudinal ALS biomarker cohorts, must be understood. Appropriate application of multimodal approaches, international collaboration, presymptomatic studies, and biomarker integration into future therapeutic trials are among the essential priorities going forward. Muscle Nerve 51 : 14–18, 2015